ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Growth Hormone
Phase 3

Lenomorelin (Anamorelin)

Lenomorelin (Anamorelin)

Also known as: Anamorelin, ONO-7643, RC-1291, Adlumiz

Overview

Key Facts

Primary Goal: An orally active ghrelin receptor agonist developed primarily for cancer-related anorexia and cachexia

An orally active ghrelin receptor agonist developed primarily for cancer-related anorexia and cachexia. It stimulates appetite and increases GH secretion through selective ghrelin mimicry, and has received regulatory approval in Japan. Half-Life 7-12 hours Typical Dose 50–100 mg Frequency once daily, fasted Cycle Length 12-24 weeks (as studied in clinical trials)

Dosing Information

Half-Life

7-12 hours

Typical Dose

50–100 mg

Frequency

once daily, fasted

Cycle Length

12-24 weeks (as studied in clinical trials)

Administration Routes:

oral

Storage & Reconstitution

Unreconstituted (Powder)

Temperature15–25°C (59–77°F)
DurationUp to 3 months

Reconstituted (Mixed)

Temperature15–25°C (59–77°F)
Duration2-4 weeks

Research Summary

Phase 3

Anamorelin completed multiple Phase III trials (ROMANA 1, 2, and 3) demonstrating significant increases in lean body mass and body weight in patients with non-small cell lung cancer cachexia. It was approved in Japan in 2021 under the brand name Adlumiz. FDA approval was not pursued after the EMA declined authorization citing improvements in lean mass but insufficient evidence for functional improvement.

Frequently Asked Questions

Common questions about Lenomorelin (Anamorelin)

UK-Specific Information

Exclusive data points and guidance for UK residents using Lenomorelin (Anamorelin)

UK Lab Testing

US Lab Testing

Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With